MedTrace Logo

Effect of Tivantinib on the QTC Interval in Cancer Subjects

NCT01699061 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-02-12

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors

Conditions

Interventions

DRUG

Tivantinib

3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2

DRUG

Placebo

Placebo tablet administered with a meal twice a day on Day 1

Sponsors & Collaborators

Principal Investigators

  • Hamim Zahir, BPharm, PhD · Daiichi Sankyo UK Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-01-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699061 on ClinicalTrials.gov